Board summary
Key figures
31,842
Registered population
52.3% aged 18–64
32.3%
Aged 65+
ICB 20.0% · England 17.9%
0.7%
Ethnic minority (non-White)
0.1% Asian
0.0%
In IMD quintile 1
ICB 30.6% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
6,360
Hypertension register
+12.02% in 3 yrs · England +5.60%
242
SMI register
11% of Westmorland and Furness (LAD)'s
567
COPD register
Reviews -0.36% in 3 yrs
Forecast to 2030
8,269
Hypertension patients, 2030
+1,909 on today
69.5%
QRISK ≥20% on statins, 2030
+4.95pp over 3 yrs
8.1%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Cardiovascular lipid therapy trails national and local benchmarks.
Only 58.2% of patients with QRISK ≥ 20% receive lipid-lowering therapy (England 63.6%), alongside 68.5% hypertension treatment to target (England 70.3%).
Phone access diverges sharply; 717 asthma patients unreviewed.
GPPS phone access differs by 33.0 pp (Ash Trees Surgery 64.6%, Park View Surgery 97.6%), while 717 of 2,559 asthma patients lack an annual.
Diabetes HbA1c control and age-5 immunisations exceed England.
Non-frail diabetes HbA1c control rose +13.8% from 2023 to 2025 to 57.9% (England +4.4%), while age-5 MMR2 coverage reached 97.5% (England 82.8%).
Population, age and ethnicity
Patients aged 65+ comprise 32.3% of registered patients, exceeding the England average of 17.9%
Registered list size is 31,842 patients across Ash Trees Surgery (23,786) and Park View Surgery (8,056). Registered patients aged 65+ comprise 32.3% (10,276 patients), above Westmorland and Furness (LAD) (25.9%), NHS Lancashire and South Cumbria Integrated Care Board (20.0%) and England (17.9%). Ash Trees Surgery records 32.9% aged 65+, and Park View Surgery records 30.4%. Based on Census usual residents rather than registered patients, ethnicity is 99.3% White with a 0.7% ethnic minority share (Asian / Asian British 0.1%, Black / African / Caribbean / Black British 0.01%).
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Westmorland and Furness (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Westmorland and Furness LA) | 1,591 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.0% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 57.9% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Westmorland and Furness LA) | 736 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Westmorland and Furness LA) | 10.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 7.7 with 0.0% of registered patients in Core20
The PCN has an average IMD decile of 7.7, compared with 6.0 in Westmorland and Furness (LAD), 5.0 in NHS Lancashire and South Cumbria Integrated Care Board and 5.5 in England. Registered Core20 patients represent 0.0%, below the borough (9.2%), ICB (30.6%) and England (21.0%). At Ash Trees Surgery (decile 7.8) and Park View Surgery (decile 7.6), 0.0% of patients reside in Core20 deciles, yielding 0 estimated Core20 patients across 0 decile 2 LSOAs.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
242
SMI register
0.76% recorded prevalence
121
Learning disability register
0.38% recorded prevalence
14
Care homes, 407 beds
In the PCN catchment
Learning disability prevalence is 0.4% (121 patients), trailing Westmorland and Furness (LAD) (0.6%), NHS Lancashire and South Cumbria Integrated Care Board (0.6%) and England (0.6%). Severe mental illness records 242 patients (0.8%). Catchment care homes number 14 with 407 beds, while district rough sleeping in Westmorland and Furness was 14 in autumn 2025.
Severe mental illness: physical health checks
SMI blood pressure checks reached 78.2% (Ash Trees Surgery 76.7%, England 83.4%), falling 7.4 pp from 2023 to 2025 (England +4.4 pp). Alcohol recording was 64.5% (England 81.8%) and BMI checks 75.4% (England 82.1%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,360
Hypertension register
+12.02%
Register growth, 3 yrs
Westmorland and Furness (LAD) +6.93% · England +5.60%
+4.85pp
BP control, under 80
≤140/90 · +0.32pp aged 80+
+1,909
More patients by 2030
Forecast 8,269 (25.01%)
Hypertension case-finding and control
Recorded hypertension prevalence is 19.9% (6,360 patients), exceeding England (15.2%), Westmorland and Furness (LAD) (18.2%) and NHS Lancashire and South Cumbria Integrated Care Board (17.2%), though crude rates are not age-adjusted. Blood pressure checks reach 91.2% (England 90.0%). However, treatment to target is 68.5% (England 70.3%, Westmorland and Furness (LAD) 71.7%), with Ash Trees Surgery at 66.7% and Park View Surgery at 75.2%. Control is 76.2% for patients aged 80+ (England 81.2%) and 65.4% for patients aged under 80 (England 67.8%). Blood pressure control trails national benchmarks despite high check rates, indicating potential benefit from targeted medication titration, particularly for patients aged 80 and over.
Lipids and statins
The PCN treats 58.2% of patients with QRISK ≥ 20% with lipid-lowering therapy, below England (63.6%) and Westmorland and Furness (LAD) (59.6%), alongside 63.3% of CKD patients (England 70.3%). Fewer high-risk patients receive lipid-lowering therapy than national rates indicate, showing an opportunity to review eligible cohorts.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 90,609 | £1.30 | £1.64 | £1.86 | £117,792 |
| Cardiovascular (all), 2025 | 128,179 | £2.89 | £3.38 | £3.33 | £370,437 |
In 2026, the PCN prescribed 90,609 lipid-regulating drug items at £1.30 per item (England £1.86, Westmorland and Furness (LAD) £1.68, NHS Lancashire and South Cumbria Integrated Care Board £1.64), spending £50,741 less than at England's unit cost. Lower unit cost than comparators does not establish efficiency, but confirms PCN spend per item sits below national rates.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
0.00%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.45%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 8.4% (2,559 patients), exceeding England (6.6%) and Westmorland and Furness (LAD) (7.9%). The review rate is 72.0% (England 65.7%), leaving an estimated 717 patients without a recorded review, while paediatric asthma prescribing is 1,942 items per 1,000 aged 5-19 (England 1,488). The 567-patient COPD register (1.8%) fell 7.2% from 2023 to 2025 (England +2.6%), though 83.8% received a review (England 76.4%). Prioritising unreviewed asthma patients and validating register trends across respiratory conditions remain key operational priorities.
Cancer register and children's immunisation
Cancer prevalence is 6.6% (2,103 patients), exceeding England (3.8%) and Westmorland and Furness (LAD) (5.3%). In Q1 2025/26 childhood immunisations, 6-in-1 coverage is below the 95.0% target by 2.9 pp at 12 months (92.1%) and by 5 pp at 24 months (90.0%), while age 5 coverage reaches 97.5% for MMR dose 2 and 95.0% for 4-in-1 booster. Infant course completion lags behind targets, showing a need for early scheduling.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022, 52.4% of staged cancers across NHS Lancashire and South Cumbria ICB were diagnosed at stage 1 or 2 (4,642 of 8,863 cases), below England (55.3%) and below the 75.0% national ambition by 22.6 pp. Across the ICB, reaching 75.0% would require about 2,010 additional early-stage diagnoses annually. Between 2013 and 2022, the ICB early-stage share fell 1.2 pp. Known-stage completeness was 74.6% (8,863 of 11,883 cancers), exceeding England (67.0%). These system figures describe ICB performance rather than PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), University Hospitals of Morecambe Bay NHS Foundation Trust recorded 78.4% on 28-day faster diagnosis and 72.4% on 62-day treatment, below the 85.0% standard by 12.6 pp (ICB 73.6%, England 71.2%). Blackpool Teaching Hospitals NHS Foundation Trust achieved 67.5% and Lancashire Teaching Hospitals NHS Foundation Trust 75.0%. For diagnostic tests in July 2026, 10.4% waited 6+ weeks at University Hospitals of Morecambe Bay NHS Foundation Trust (Blackpool Teaching Hospitals NHS Foundation Trust 26.5%, Lancashire Teaching Hospitals NHS Foundation Trust 26.7%, England 23.1%). These provider figures do not measure PCN performance.
| Pathways within standard (%) | of Morecambe Bay | Blackpool | Lancashire | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 78.39 | 71.38 | 82.90 | 78.39 | 79.32 |
| 31-day treatment (96%) | 95.22 | 97.96 | 89.43 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 72.35 | 67.48 | 75.04 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | of Morecambe Bay | Blackpool | Lancashire | England |
|---|---|---|---|---|
| MRI | 4.04 | 21.80 | 2.41 | 21.40 |
| CT | 13.76 | 16.49 | 14.97 | 9.92 |
| Echocardiography | 10.55 | 7.57 | 13.85 | 28.48 |
| Colonoscopy | 0.60 | 13.08 | 0.00 | 30.83 |
| Gastroscopy | 1.45 | 12.47 | 0.00 | 29.02 |
| All 15 DM01 tests | 10.44 | 26.54 | 26.65 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In June 2026 (provisional), Westmorland and Furness residents accounted for 249,980 community care activities and 53,485 care contacts, out of 533,345 activities and 193,720 contacts across NHS Lancashire and South Cumbria Integrated Care Board. Adults aged 65+ accounted for 67.9% of borough contacts (36,330). These experimental figures describe local authority resident activity rather than PCN registered patients.
Practice variation and patient experience
Phone access diverges by 33.0 pp across practices despite similarly high overall satisfaction
In 2025/26, overall QOF achievement reached 94.0% at Ash Trees Surgery and 96.7% at Park View Surgery (England 92.5%). Clinical-domain achievement was 95.9% at Ash Trees Surgery and 99.5% at Park View Surgery. Vaccination and immunisation achievement was 74.5% at Park View Surgery, while achievement reached 75.0% at Ash Trees Surgery (a 0.4 pp range), with both exceeding England's 55.2%.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Park View Surgery | 107 | 0.0 | 97.6% | 67.7% | 85.1% |
| Ash Trees Surgery | 123 | 0.0 | 64.6% | 79.1% | 82.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Severe mental illness checks fell up to 19.6 pp while diabetes control reached 57.9%
From 2023 to 2025, severe mental illness physical health monitoring trailed England: psychosis alcohol recording fell 19.6 pp to 64.5% (England +5.4 pp to 81.8%), smoking cessation offers fell 15.1 pp to 79.0% (England +0.1 pp to 94.2%), mental health BMI recording fell 8.7 pp to 75.4% (England +5.1 pp), and blood pressure checks fell 7.4 pp to 78.2% (England +4.4 pp). Conversely, non-frail diabetes HbA1c control grew +13.8% over three years (England +4.4%) to 57.9%, and learning disability registers grew +27.0% (England +5.4%) to 121 patients.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Alcohol record (psychosis)
Smoking support (SMI)
BMI record (SMI)
BP check (SMI)
COPD register
Diabetes HbA1c control
Diabetes statin (no CVD)
BP control, under 80
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Westmorland and Furness (LAD) | Asset | PCN | Westmorland and Furness (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 14 (407 beds) | n/a | Schools (catchment) | 37 | n/a |
| Children's centres | 3 | 12 | Places of worship | 58 | 316 |
| Libraries | 5 | 14 | Food banks (VCS) | n/a | 2 |
| Day centres (VCS) | n/a | 2 | Children and young people (VCS) | n/a | 3 |
| Carers support groups (VCS) | n/a | 2 | Primary schools (LA maintained) | 20 | 82 |
| Primary academies | 2 | 27 | Special schools | 1 | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma review and prescribing recall
72.0% of the 2,559 asthma patients had a review (England 65.7%, LAD 70.4%), leaving an estimated 717 unreviewed. For discussion, the PCN could run structured asthma recall and inhaler checks across Ash Trees Surgery (23,786) and Park View Surgery (8,056). Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Learning disability register validation
Learning disability prevalence is 0.4% (121 of 31,842 patients) versus 0.6% across LAD, ICB and England (+55 to +66 benchmark gap). For discussion, practices could audit diagnostic codes and cross-check social-care records where sharing exists across Ash Trees Surgery (23,786) and Park View Surgery (8,056). Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Option 3
COPD register and spirometry review
COPD prevalence is 1.8% (567 of 31,842 patients) versus 1.9% in England and 2.0% in LAD (+36 to +75 benchmark gap). For discussion, practices could search for symptomatic smokers with repeat inhalers lacking a code and raise spirometry access with system partners. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register audit (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Clinical register vulnerability outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health review recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension medication titration review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Early infant immunisation recall (p6) | 6-in-1 complete primary course at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| System early diagnosis audit (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Telephony access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Asthma review and prescribing recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Learning disability register validation (p12) | Registered population · Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Option 3 · COPD register and spirometry review (p12) | Registered population · COPD register · COPD: QOF prevalence | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
